← Eichor
Condition: Refractory Relapse Neuroblastoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Refractory Relapse Neuroblastoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 · 13 location(s) · New Approaches to Neuroblastoma Therapy Consortium · NCT06450041Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Phase 1 · 2 location(s) · Nanjing Children's Hospital · NCT06751134A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Pat
Phase 2 · 4 location(s) · St. Jude Children's Research Hospital · NCT07085338Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03721068Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
EARLY_Phase 1 · 2 location(s) · Sichuan University · NCT07067346Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Phase 1 · 1 location(s) · Stanford University · NCT06500819Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Phase 1/Phase 2 · 2 location(s) · Roberto Chiarle · NCT06803875NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Phase 1/Phase 2 · 1 location(s) · Nationwide Children's Hospital · NCT04211675Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/Phase 2 · 22 location(s) · Milton S. Hershey Medical Center · NCT06541262NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neurob
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT07211737Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Phase 1 · 1 location(s) · Kyushu University · NCT05608148Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors
Phase 1/Phase 2 · 3 location(s) · Sun Yat-Sen University Cancer Center · NCT06836505PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Theodore Laetsch · NCT06721689GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT05650749GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Phase 1 · 1 location(s) · Stanford University · NCT07087002Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Phase 1/Phase 2 · 12 location(s) · Milton S. Hershey Medical Center · NCT06465199Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Phase 2 · 12 location(s) · Giselle Sholler · NCT06540963Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neurobla
Phase 1 · 1 location(s) · Jagiellonian University · NCT05272371A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
EARLY_Phase 1 · 1 location(s) · The General Hospital of Western Theater Command · NCT06684639Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumor
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT02508038Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 · 3 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT01804634Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or R
Phase 1 · 2 location(s) · Steven DuBois, MD · NCT07027748Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Ris
Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07375563Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Phase 1 · 2 location(s) · Children's National Research Institute · NCT07172958Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Phase 2 · 5 location(s) · Jakob Stenman · NCT04903899Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refra
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06995872Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07502287Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07318831
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.